Leukemia Treatment Breakthrough

Adding Rituxan to standard chemotherapy for chronic lymphocytic leukemia raises three-year survival to 65% and is now the gold standard therapy for most patients.

Click here to read the full story.

Post a Comment

No comments yet!
Inergize Digital This site is hosted and managed by Inergize Digital.
Mobile advertising for this site is available on Local Ad Buy.